Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022:2455:1-18.
doi: 10.1007/978-1-0716-2128-8_1.

Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH)

Affiliations

Histopathological Diagnosis of Nonalcoholic Steatohepatitis (NASH)

Shah Giashuddin et al. Methods Mol Biol. 2022.

Abstract

Nonalcoholic steatohepatitis (NASH) is part of a spectrum of conditions collectively referred to as nonalcoholic fatty liver disease (NAFLD). NASH/NAFLD is the most common chronic liver disease. NASH is defined as ≥5% hepatic steatosis along with hepatocellular injury. Histopathological features that indicate hepatocellular injury in NASH include ballooning degeneration, lobular inflammation, and apoptotic bodies. Scoring schemes, such as the NASH Clinical Research Network (CRN), use those histopathological features to grade the severity of the disease and determine a stage based on the amount of fibrosis. Among the NAFLD spectrum, NASH has the highest risk of developing fibrosis and progressing to liver cirrhosis. Therefore, accurate and timely diagnosis is crucial in order to initiate therapy and prevent disease complications as well as liver-related mortality. Although several imaging modalities and laboratory assays have been introduced to diagnose NASH, a liver biopsy remains the gold standard for diagnosing, grading, and staging the disease.

Keywords: Ballooning degeneration; Hepatic steatosis; NASH Clinical Research Network; NASH cirrhosis; NASH histopathology; Nonalcoholic fatty liver disease (NAFLD); Nonalcoholic steatohepatitis (NASH).

PubMed Disclaimer

References

    1. Burt AD, Portmann B, Ferrell LD (2012) MacSween's pathology of the liver, 6th edn. Churchill Livingstone/Elsevier, Edinburgh
    1. Saxena R (ed) (2011) Practical hepatic pathology: a diagnostic approach, 1st edn. Elsevier Saunders, Philadelphia, PA
    1. Chalasani N, Younossi Z, Lavine JE et al (2018) The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases. Hepatology 67:328–357 - DOI
    1. Parthasarathy G, Revelo X, Malhi H (2020) Pathogenesis of nonalcoholic steatohepatitis: an overview. Hepatol Commun 4:478–492 - DOI
    1. Neuschwander-Tetri BA, Caldwell SH (2003) Nonalcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology 37:1202–1219 - DOI

LinkOut - more resources